. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: J Clin Pharmacol. 2014 Apr 8;54(9):1063–1071. doi: 10.1002/jcph.298

Table 2.

Total and Unbound Atazanavir and Darunavir Concentrations in Plasma and CSF

	Atazanavir (n = 13)^*		Darunavir (n = 14)^*
	Geometric Mean or Ratio	95%CI	Geometric Mean or Ratio	95%CI
Total drug concentrations
Plasma (ng/mL)	295.8	204.2–428.3	1907.0	1461.0–2491.2
CSF (ng/mL)	8.7	7.2–10.5	8.5	6.0–12.1
CSF/plasma ratio	0.03	0.02–0.04	0.005	0.004–0.006
Unbound drug concentrations
Plasma (ng/mL)	7.1	5.1–10.0	54.4	42.1–70.4
CSF (ng/mL)	0.6	0.4–0.9	2.3	1.4–3.7
CSF/plasma ratio	0.09	0.06–0.1	0.04	0.03–0.06

CSF, cerebrospinal fluid; CI, confidence interval.

Participants with total plasma drug concentrations <50 ng/mL were excluded from analyses due to medication nonadherence, resulting in n = 13 for ATV and n = 14 for DRV.